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Conclusions: Our	 data	 confirm	 that	 the	 course	 of	 SARS-	CoV-	2	 infection	 in	
	patients	with	CML	 is	generally	mild	and	 reassure	about	 the	 safety	of	 continu-
ing	TKIs	during	the	COVID-	19	pandemic.	Furthermore,	we	suggest	that	patients	
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1 	 | 	 INTRODUCTION
The	 clinical	 course	 of	 the	 2019	 coronavirus	 (SARS-	
CoV-	2)	 disease	 (COVID-	19)	 is	 extremely	 hetero-
geneous,	 with	 infected	 individuals	 being	 either	
asymptomatic	 or	 developing	 severe	 acute	 respiratory	
manifestations.1  Patients	 with	 hematological	 malig-
nancies	 are	 at	 an	 increased	 risk	 of	 severe	 COVID-	19	
and	 unfavorable	 outcome.2	 However,	 comparing	 the	







Imatinib,	 the	 first	 generation	 tyrosine	 kinase	 in-
hibitor	 (TKI)	 has	 dramatically	 changed	 the	 history	
of	 CML	 treatment,	 increasing	 the	 rates	 of	 molecular	
responses,	reducing	the	likelihood	of	natural	progres-
sion	 of	 CML	 from	 chronic	 to	 advanced	 phases,	 and	
improving	the	survival.4,5	Other	BCR-	ABL1	inhibitors,	
namely	nilotinib,	dasatinib,	bosutinib,	and	ponatinib,	
have	 been	 subsequently	 developed	 to	 overcome	 the	
resistance	 or	 intolerance	 to	 imatinib.6-	9	 Still	 limited	
evidence	 suggests	 that	 some	of	 these	drugs	may	have	
a	 direct	 anti-	viral	 action	 of	 an	 indirect	 effect	 on	 the	
host	 response	 to	 SARS-	CoV-	2	 infection,	 and	 ongoing	
trials	 aim	 at	 verifying	 the	 effect	 of	 TKIs	 in	 prevent-
ing	 pulmonary	 vascular	 leak	 in	 patients	 with	 severe	
COVID-	19	pneumonia.10
To	 date,	 the	 prevalence	 of	 SARS-	CoV-	2	 infection	 in	
patients	with	CML	has	been	reported	through	the	collec-
tion	of	 infected	cases,	 as	determined	by	molecular	 test-
ing	on	symptomatic	individuals	and/or	contacts	through	
qRT-	PCR	 on	 pharyngeal	 swabs,	 and	 estimating	 the	 fre-
quency	 over	 the	 total	 number	 of	 patients	 followed	 at	
each	 center,	 without	 direct	 evaluation	 of	 asymptomatic	
patients.	The	 reported	 prevalence	 in	 these	 studies,	 con-
ducted	during	the	first	months	of	pandemic,	ranged	from	
0.17%	to	0.9%.11-	15
The	 seroprevalence	 of	 SARS-	CoV-	2	 infection	 in	 a	
cohort	 of	 patients	 with	 CML,	 including	 symptomatic	
and	 asymptomatic	 individuals,	 has	 not	 been	 reported	
yet.
2 	 | 	 METHODS
2.1	 |	 Study procedures
In	this	experimental,	cross-	sectional,	non-	pharmacological	
study	 we	 enrolled	 all	 consecutive	 patients	 with	 CML	 at-
tending	 five	 outpatient	 hematological	 centers	 in	 three	
Italian	 regions	 with	 different	 prevalence	 of	 infection	 in	
the	 general	 population	 (Veneto,	 Friuli-	Venezia	 Giulia,	
and	 Lazio).	 The	 inclusion	 criteria	 comprehended	 an	 es-
tablished	diagnosis	of	CML	according	to	the	World	Health	
Organization	criteria	and	age	≥18 years.	No	exclusion	cri-
teria	 have	 been	 envisaged,	 except	 for	 the	 unwillingness	
to	 sign	 a	 written	 informed	 consent.	 Patients	 enrolled	 in	
clinical	 trials	 were	 not	 excluded	 unless	 the	 participation	




COVID-	19	 (travels,	 occupational	 exposure,	 living	 with	
infected	 individuals)	 and	 respiratory	 or	 general	 symp-
toms	 experienced	 from	 mid-	February	 2020,	 patients	
were	 tested	 for	 anti-	SARS-	CoV-	2	 IgM	 and/or	 IgG	 anti-






2.2	 |	 Comparison group
The	 prevalence	 of	 SARS-	COV-	2	 infection	 in	 the	 gen-
eral	 population	 was	 retrieved	 from	 the	 Istat-	Italian	
Ministry	 of	 Health,	 SARS-	CoV-	2  seroprevalence	 study,	
which	 was	 conducted	 between	 May	 and	 July	 2020	 on	
64,660	 individuals,	 and	 estimated	 an	 anti-	SARS-	CoV-	2	
IgG	 Italian	 prevalence	 of	 2.5%,	 with	 marked	 regional	
differences	 ranging	 from	 0.3%	 (Sicily	 and	 Sardinia)	 to	
7.5%	 (Lombardy).	As	of	15  July	2020	 the	prevalence	of	
SARS-	CoV-	2	 infection	 in	 the	 three	 regions	 involved	 in	
the	 present	 study	 was	 1.9	 (95%CI	 1.4–	2,5)	 for	 Veneto,	
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2.3	 |	 Statistical analysis
Epidemiological	and	serological	patterns	were	compared	
using	the	chi-	squared	test	for	differences	in	terms	of	cat-
egorical	 variables	 (or	 Fisher's	 exact	 test	 when	 appropri-
ated),	 t-	test	 or	 Mann–	Whitney	 test	 (when	 appropriated)	
for	 difference	 in	 terms	 of	 continuous	 variables.	 For	 all	
hypotheses	tested,	two-	tailed	p	values < 0.05	were	consid-
ered	to	be	significant.
3 	 | 	 RESULTS
3.1	 |	 Study population
From	 18  May	 2020	 to	 3  November	 2020	 a	 total	 of	 564	
	patients	with	CML	were	 tested.	None	refused	 to	partici-
pate.	 Patients	 enrolled	 in	 ongoing	 experimental	 clinical	




63.6	 (range	 19.6–	93.9)	 years,	 and	 the	 median	 time	 since	
CML	diagnosis	was	8.6	(range	0.1–	33.7)	years.
Sokal	 risk	 distribution	 was	 41%,	 37%,	 and	 14%	 for	
L/I/H	 categories,	 respectively	 (8%	 not	 available).	 Nearly	
half	of	 the	patients	were	on	 the	 first-	line	TKI	 treatment	
(n  =  281,	 49.8%),	 while	 the	 remainders	 were	 on	 second	
line	(n = 131,	23.2%),	 third,	or	 further	 line	of	 treatment	
(n  =  58,	 10.3%),	 or	 in	 treatment-	free	 remission	 (TFR)	
(n = 94,	16.7%).
The	type	of	TKI	currently	taken	was	imatinib	(n = 205,	
43.6%),	 nilotinib	 (n  =  114,	 24.1%),	 dasatinib	 (n  =  85,	










tion	 of	 1.95%	 (95%CI	 1.09–	3.46),	 which	 was	 close	 to	 the	
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one	from	Lazio;	the	estimated	prevalence	of	 infection	in	
the	 three	 regions	 was	 2.7%,	 1%,	 and	 0.8%,	 respectively,	
which	was	comparable	 to	 the	general	population	also	at	
the		regional	level.
3.3	 |	 Serological status and modality of 
CML treatment





3.4	 |	 Serological status and risk factors 
for SARS- CoV- 2 infection
Active	workers	were	43%	of	the	enrolled	patients	in	the	
entire	cohort,	and	the	remainders	were	retired	(42.5%),	












3.5	 |	 Serological status and symptoms
Overall,	 the	frequency	of	new	onset	or	worsening	symp-
toms	 reported	 during	 the	 last	 months	 was	 as	 follows:	
anosmia	(2.3%),	ageusia	(1.8%),	cough	(5.3%),	pharyngitis	
(4.3%),	dyspnea	(3.4%),	fever	(4.4%),	headache	(7.8%),	as-






4 	 | 	 DISCUSSION





F I G U R E  1  Treatment	modalities	(frequency	of	each	TKI,	or	TFR	status)	in	the	total	CML	cohort	(left	panel)	and	in	patients	with	
positive	anti-	SARS-	CoV-	2 serological	test	(right	panel)













the	 Italian	 Campus	 CML	 program,	 comprising	 6,883	 pa-






and	 uninfected	 patients,	 including	 the	 type	 of	TKI	 treat-
ment.	The	study	was	promoted	by	the	University	of	Verona	
and	 other	 two	 representative	 Venetian	 Centers	 were	 in-
volved	 in	 the	project	 since	 the	Veneto	 region	was	one	of	














In	 vitro	 studies	 and	 limited	 clinical	 evidence	 suggest	
that	TKIs	may	have	a	direct	antiviral	action	and/or	indirect	




















diagnosed	as	having	COVID-	19	 infection,	and	 in	all	 these	
















Anosmia 5	(45.5) 8	(1.5) <0.001
Ageusia 5	(45.5) 5	(0.9) <0.001
Cough 3	(27.3) 27	(4.9) 0.017
Pharyngitis 2	(18.2) 22	(4.0) 0.075
Dyspnea 0 19	(3.4) ns
Fever 4	(36.4) 21	(3.8) <0.001
Headache 2	(18.2) 42	(7.6) 0.21
Asthenia 5	(45.5) 69	(12.5) 0.008
Arthralgia 5	(45.5) 69	(12.5) 0.008
Dizziness 4	(36.4) 31	(5.6) 0.003
Nausea/vomiting 0 15	(2.7) ns
Diarrhea 1	(9.1) 26	(4.7) 0.42
T A B L E  2 	 Correlation	of	new	onset	
or	worsening	symptoms	and	serological	
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of	inflammatory	cytokines,	which	are	ultimately	respon-
sible	for	organ	failure.	Due	to	the	limited	number	of	sub-
jects	 exposed	 to	 SARS-	CoV-	2	 in	 the	 general	 population	

















a	 single	 study	 center	 for	 the	 Friuli-	Venezia	 Giulia	 and	
Lazio	regions	may	limit	the	generalization	of	our	findings.	
However,	 these	 centers	 of	 reference	 for	 CML	 manage	 a	




CoV-	2	 IgM	 and/or	 IgG	 positivity	 in	 patients	 with	 CML	
was	 comparable	 to	 the	 general	 population	 in	 the	 same	
period	both	at	national	and	regional	levels,	and	reassure	
about	the	safety	of	continuing	TKI	treatment	in	patients	
with	 CML	 during	 the	 ongoing	 SARS-	CoV-	2	 pandemic.	
Furthermore,	 our	 data	 suggest	 that	 patients	 with	 CML,	
whether	 on	TKI	 treatment	 or	 not,	 are	 able	 to	 mount	 an	
antibody	 response	 after	 exposure	 to	 SARS-	CoV-	2.	 This	
observation	 might	 imply	 that	 in	 patients	 with	 CML	 the	
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